EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH ‐Dx V2.0 and the WHO Skin5

Lyn M Duncan iD, David E Elder iD, Michael W Piepkorn, Stevan R Knezevich, Willeke A M Blokx, Marcus Bosenberg, Klaus J Busam iD, Richard Carr, Martin G Cook, Pedram Gerami, Jennifer Ko iD, Gilles Landman and 9 more

Journal of Cutaneous Pathology · 2026

DOI: 10.1111/cup.14788 ↗

At a glance

Übersichtsarbeit in Journal of Cutaneous Pathology, 2026. Written by Lyn M Duncan and 20 co-authors. Institution: Harvard Medical School, Dermatopathology Unit, Pathology Service, Massachusetts General Hospital, Boston, Massachusetts, USA. Major MEDLINE topics: Melanoma, Skin Neoplasms, Terminology as Topic, Nevus, Pigmented. Cited 3 times so far (Crossref); 47 references. Funded by: NHMRC Investigator Grant, National Health and Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In this Special Issue of the Journal of Cutaneous Pathology in memory of Dr. Martin C. Mihm, Jr, we highlight his many contributions over more than 50 years to the catalog of specific melanocytic tumor terminology. Dr. Mihm was an active participant in the International Melanoma Pathology Study Group (IMPSG). Discussions led to proposed recommendations for changes in the terminology of melanocytic tumors and their standardized diagnostic reporting. Histopathological reports of melanocytic tumors provide critical information that guides patient counseling and therapy. Importantly the pathology report must relay whether the melanocytic tumor is benign, intermediate, or malignant, and when appropriate, indicate diagnostic and/or prognostic uncertainty. Recent shifts in diagnostic terminology include the recommended use of the term “melanocytoma” to describe a morphologically and genetically defined subset of intermediate risk melanocytic tumors with higher (although still very low) risk of progression compared with benign nevi. Melanocytomas are distinguished from melanocytic tumors of uncertain malignant potential (MELTUMP) which are histopathologically indeterminate or uncertain tumors. In the setting of a broad lexicon for the reporting of melanocytic tumors, an assessment tool has been developed to map existing diverse terminologies into distinct hierarchical classes. The Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH‐Dx) V2.0 provides a four‐tiered classification scheme that is tiered by risk of tumor progression and recommended treatment. The purpose of this review is to report these shifts in diagnostic terminology, discussed and reviewed at the annual workshop of the IMPSG, in Edinburg, Scotland, in November 2022. This discussion included the use of the term melanocytoma, and the use of the MPATH‐Dx V2.0 classification and terminology for melanocytic tumors. Dr. Mihm was diligent in his attention to specific terminology, in his memory we aim to recommend terminology that improves communication in the care of those diagnosed with melanocytic tumors.

Subjects

MeSH terms (MEDLINE)

MelanomaSkin NeoplasmsTerminology as TopicNevus, PigmentedHumansWorld Health OrganizationMelanocytes

Author keywords

Spitzmelanocytomamelanomanevusterminology

Authors and institutions

  • Harvard Medical School, Dermatopathology Unit, Pathology Service, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Dermatology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Dermatopathology Northwest, Bellevue, Washington, USA.
  • Pathology Associates, Clovis, California, USA.
  • Division Laboratories, Department of Pathology, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.

ORCID profiles: Lyn M Duncan, David E Elder, Klaus J Busam, Jennifer Ko, Lori Lowe, Daniela Mihic-Probst, Christopher R Shea

Funding

  • NHMRC Investigator Grant
  • National Health and Medical Research Council

Cite

APA

Duncan, L. M., Elder, D. E., Piepkorn, M. W., Knezevich, S. R., Blokx, W. A. M., Bosenberg, M., Busam, K. J., Carr, R., Cook, M. G., Gerami, P., Ko, J., Landman, G., Lazar, A. J., Lowe, L., Mihic-Probst, D., Schmidt, B., Shea, C. R., Scolyer, R. A., Xu, X., …, & Barnhill, R. L. (2026). Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH ‐Dx V2.0 and the WHO Skin5. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14788

Vancouver

Duncan LM, Elder DE, Piepkorn MW, Knezevich SR, Blokx WAM, Bosenberg M, et al. Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH ‐Dx V2.0 and the WHO Skin5. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.14788

BibTeX
@article{Duncan2026,
  author = {Duncan, Lyn M and Elder, David E and Piepkorn, Michael W and Knezevich, Stevan R and Blokx, Willeke A M and Bosenberg, Marcus and Busam, Klaus J and Carr, Richard and Cook, Martin G and Gerami, Pedram and Ko, Jennifer and Landman, Gilles and Lazar, Alexander J and Lowe, Lori and Mihic-Probst, Daniela and Schmidt, Birgitta and Shea, Christopher R and Scolyer, Richard A and Xu, Xiaowei and Elmore, Joann G and Barnhill, Raymond L},
  title = {Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH ‐Dx V2.0 and the WHO Skin5},
  journal = {Journal of Cutaneous Pathology},
  year = {2026},
  doi = {10.1111/cup.14788}
}
Start for free →